| 来源类型 | Blog |
| 规范类型 | 其他 |
| Discounted drugs vs. Big Pharma | |
| Hagop M. Kantarjian | |
| 发表日期 | 2015-11-10 |
| 出版年 | 2015 |
| 语种 | 英语 |
| 概述 | The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under ... |
| 摘要 | The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under attack — primarily by pharmaceutical companies, which stand to increase profits if the program is curtailed. Dr. Hagop Kantarjian, chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center and a Baker Institute health policy fellow, and Dr. Robert Chapman, medical director of the Josephine Ford Cancer Institute at the Henry Ford Health System, provide background and support for the program in the Baker Institute Blog. |
| 主题 | Domestic Health Policy |
| URL | https://www.bakerinstitute.org/research/drug-discount-program-medical-lifeline/ |
| 来源智库 | James A. Baker III Institute for Public Policy (United States) |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/79589 |
| 推荐引用方式 GB/T 7714 | Hagop M. Kantarjian . Discounted drugs vs. Big Pharma. 2015. |
| 条目包含的文件 | 条目无相关文件。 | |||||
| 个性服务 |
| 推荐该条目 |
| 保存到收藏夹 |
| 导出为Endnote文件 |
| 谷歌学术 |
| 谷歌学术中相似的文章 |
| [Hagop M. Kantarjian ]的文章 |
| 百度学术 |
| 百度学术中相似的文章 |
| [Hagop M. Kantarjian ]的文章 |
| 必应学术 |
| 必应学术中相似的文章 |
| [Hagop M. Kantarjian ]的文章 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
